Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
06/2012
06/05/2012CA2530779C Acapsular p. multocida hyae deletion mutants
06/05/2012CA2519787C Methods of treating diabetes by blocking vegf-mediated activity
06/05/2012CA2519113C Antibodies against insulin-like growth factor i receptor and uses thereof
06/05/2012CA2423983C An immunogenic iscom complex comprising an enzymatically active a1 subunit of the cholera toxin or e. coli heat labile enterotoxin fused to a dimer of the d region of protein a
06/05/2012CA2403701C Recombinant parainfluenza virus expression systems and vaccines
06/05/2012CA2397359C Composition of antigen and glycolipid adjuvant sublingual administration
06/05/2012CA2368670C Modulation of vascular permeability by means of tie2 receptor activators
06/05/2012CA2366455C Immunoadsorber for use in sepsis therapy
06/05/2012CA2264939C Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
06/05/2012CA2249352C Immunoliposomes that optimize internalization into target cells
06/05/2012CA2248667C Hla-a2.1 binding peptides and their uses
06/05/2012CA2233534C Manipulation of non-terminally differentiated cells using the notch pathway
05/2012
05/31/2012WO2012071573A2 Materials and methods for the prevention and treatment of cancer
05/31/2012WO2012071561A2 Anti-il-6 antibodies for the treatment of anemia
05/31/2012WO2012071554A2 Anti-il-6 antibodies for the treatment of oral mucositis
05/31/2012WO2012071521A2 Adjuvant
05/31/2012WO2012071413A2 Assembly and method for coronary sinus cannulation
05/31/2012WO2012071411A2 Nk cell modulating treatments and methods for treatment of hematological malignancies
05/31/2012WO2012071381A1 Antibodies to notum pectinacetylesterase
05/31/2012WO2012071372A2 Human antibodies to the glucagon receptor
05/31/2012WO2012071346A1 Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
05/31/2012WO2012071216A2 Antibodies for tumor gangliosides
05/31/2012WO2012071097A1 Methods for diagnosing and treating neuroendocrine cancer
05/31/2012WO2012071042A1 Compositions and methods for treating or preventing lupus
05/31/2012WO2012070974A1 Vaccines with enhanced immunogenicity and methods for the production thereof
05/31/2012WO2012070973A1 Method for treating cancer patients
05/31/2012WO2012070972A1 Method for treating cardiovascular disease patients
05/31/2012WO2012070970A1 Diagnostic method for predicting the development of cancerous diseases and monitoring treatment efficacy
05/31/2012WO2012070969A1 Diagnostic method for predicting the development of cardiovascular diseases and monitoring treatment efficacy
05/31/2012WO2012070029A1 A pharmaceutical composition
05/31/2012WO2012069638A1 Nucleic acids encoding prrsv gp5-ecto domain and m protein
05/31/2012WO2012069550A1 Novel homogeneous humanized antiproliferation antibodies
05/31/2012WO2012069462A1 Biomarkers for predicting the efficacy of an immunotherapy against cancer
05/31/2012WO2012069067A1 Method for producing an immunotherapeutic agent
05/31/2012WO2012068637A1 Compositions and methods
05/31/2012WO2012068636A1 Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system
05/31/2012WO2012068630A1 Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system following a stroke
05/31/2012WO2012047317A3 Tumor specific antibodies and uses therefor
05/31/2012WO2012046009A8 Composition for intraocular implantation of bevacizumab
05/31/2012WO2012045882A3 Phosphospecific antibodies recognising tau
05/31/2012WO2012037485A9 Methods of inhibiting alphavirus replication and treating alphavirus infection
05/31/2012WO2012035558A3 A synthetic immunogen useful for generating long lasting immunity and protection against pathogens
05/31/2012WO2012034025A3 Human cytomegalovirus vaccine
05/31/2012WO2012030904A3 Human immunodeficiency virus (hiv)-neutralizing antibodies
05/31/2012WO2012027328A3 Anti-ox40 antibodies and methods of using the same
05/31/2012WO2012026878A8 Monoclonal antibody specific to major neutralizing epitope of influenza h5 hemagglutinin
05/31/2012WO2012024621A3 Synthetic nanocarrier vaccines comprising peptides obtained or derived from human influenza a virus hemagglutinin
05/31/2012WO2012018877A9 Treating breast cancer with anti-il-19 antibody
05/31/2012WO2012006634A3 Prostate specific antigen (psa) peptide therapy
05/31/2012WO2011157447A3 Modified parvovirus having enhanced anti-tumour efficacy
05/31/2012WO2011154976A3 Improved influenza vaccine
05/31/2012WO2011146933A3 Universal dengue virus sequences and methods of use
05/31/2012WO2011146891A3 High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
05/31/2012WO2011143653A3 Recombinant hcmv and rhcmv vectors and uses thereof
05/31/2012WO2011140132A9 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
05/31/2012WO2005018539A8 Influenza hemagglutinin and neuraminidase variants
05/31/2012US20120137378 Extraneous agents testing
05/31/2012US20120136338 Immunologic compounds for prevention, protection, prophylaxis or treatment of immunological disorders, infections and cancer
05/31/2012US20120136142 Vaccine Compositions For Marburg Virus
05/31/2012US20120135501 Recombinant poxvirus expressing homologous genes inserted
05/31/2012US20120135496 Protein Belonging to the TNF Superfamily Involved in Signal Transduction, Nucleic Acids Encoding Same and Methods of Use Thereof
05/31/2012US20120135422 Anti-gpcr antibody and the method of producing the same
05/31/2012US20120135070 Copolymers
05/31/2012US20120135067 Vaccine for mycoplasma infection
05/31/2012US20120135064 Conjugated nanodelivery vehicles
05/31/2012US20120135063 Glucuronic acid-containing glucan, process for production of same, and use of same
05/31/2012US20120135040 Temperature sensitive vaccine strain of mycoplasma hyopneumoniae and uses thereof
05/31/2012US20120135039 Oral Vaccines for Producing Mucosal Immunity
05/31/2012US20120135038 Expression of protective antigens in transgenic chloroplasts and the production of improved vaccines
05/31/2012US20120135037 Flagellin fusion proteins and conjugates comprising pneumococcus antigens and methods of using the same
05/31/2012US20120135035 Induction of an immune response against dengue virus using the prime-boost approach
05/31/2012US20120135034 Non-Integrating Retroviral Vector Vaccines
05/31/2012US20120135033 Multiple delivery system for heterologous antigens
05/31/2012US20120135032 Generation of a broad t-cell response in humans against hiv
05/31/2012US20120135031 Method of enhancing an immune response
05/31/2012US20120135030 Method of Producing Protein-Carbohydrate Vaccines Reduced in Free Carbohydrate
05/31/2012US20120135029 Method for the purification of protein complexes
05/31/2012US20120135028 Vaccine
05/31/2012US20120135027 Proteins used for the diagnosis of lyme borreliosis
05/31/2012US20120135026 Combination neisserial compositions
05/31/2012US20120135025 Chlamydia antigens and uses thereof
05/31/2012US20120135024 Neisseria meningitidis antigens and compositions
05/31/2012US20120135023 Influenza hemagglutinin and neuraminidase variants
05/31/2012US20120135022 Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3
05/31/2012US20120135021 Cell penetrating peptides and its use fused to biomolecules with therapeutic action
05/31/2012US20120135020 Ttk peptides and vaccines including the same
05/31/2012US20120135018 Erg monoclonal antibodies
05/31/2012US20120135017 Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making
05/31/2012US20120135014 Single nucleotide polymorphisms (snp) and association with resistance to immune tolerance induction
05/31/2012US20120135012 Trans-membrane-antibody induced inhibition of apoptosis
05/31/2012US20120135011 Method for in vivo expansion of T regulatory cells
05/31/2012US20120135010 High affinity human antibodies to human il-4 receptor
05/31/2012US20120135009 Cleaved and Phosphorylated CRMP2 as Blood Marker of Inflammatory Diseases of the Central Nervous System
05/31/2012US20120135008 Methods and compositions for targeting polyubiquitin
05/31/2012US20120135007 Anti-LPS Enriched Immunoglobulin Preparations For The Treatment And/Or Prophylaxis Of A Pathologic Disorder
05/31/2012US20120135006 Ultra high affinity neutralizing antibodies
05/31/2012US20120135005 ANTI-TNF-a ANTIBODIES AND THEIR USES
05/31/2012US20120135004 Antibodies to matrix metalloproteinase 9
05/31/2012US20120135003 Anti-ilt7 antibody
05/31/2012US20120135002 Compounds and Methods for the Treatment of Cancer
1 ... 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 ... 1823